Show simple item record

dc.contributor.authorHardman, J
dc.contributor.authorLiu, Z
dc.contributor.authorBrady, G
dc.contributor.authorRoe, J
dc.contributor.authorKerawala, C
dc.contributor.authorRiva, F
dc.contributor.authorClarke, P
dc.contributor.authorKim, D
dc.contributor.authorBhide, S
dc.contributor.authorNutting, C
dc.contributor.authorHarrington, K
dc.contributor.authorPaleri, V
dc.date.accessioned2021-03-24T11:17:20Z
dc.date.available2021-03-24T11:17:20Z
dc.date.issued2020-05-01
dc.identifier.citationHead & neck, 2020, 42 (5), pp. 1089 - 1104
dc.identifier.issn1043-3074
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4443
dc.identifier.eissn1097-0347
dc.identifier.doi10.1002/hed.26100
dc.description.abstractBACKGROUND: Transoral robotic surgery (TORS) for recurrent head and neck (H&N) cancer is an emerging but relatively infrequent procedure. METHODS: Systematic review and meta-analysis of studies reporting survival data and functional outcomes for patients undergoing TORS for previously treated H&N cancers. RESULTS: Eight hundred seventy-eight records were identified, of which eight were eligible for inclusion, covering 161 cases (range 1-64). The pooled rates were as follows: 2-year overall survival 73.8% (4 studies, range 70.6-75.0, 95% confidence intervals (CI) 65.4 to 81.5, [I2 0.0%, P = 1.0]); 2-year disease-free survival 74.8% (4 studies, range 56.2-92.0, 95% CI 63.3 to 84.8, [I2 36.9%, P = .2]); postoperative hemorrhage 9.3% (4 studies, range 3.3-13.3, 95% CI 4.7 to 15.1, [I2 0.0%, P = .5]). CONCLUSIONS: Functional and oncological outcomes are favorable, although the follow-up is limited in the literature. Larger cohorts with longer follow-up are needed for definitive conclusions to be drawn.
dc.formatPrint-Electronic
dc.format.extent1089 - 1104
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleTransoral robotic surgery for recurrent cancers of the upper aerodigestive tract-Systematic review and meta-analysis.
dc.typeJournal Article
dcterms.dateAccepted2020-01-28
rioxxterms.versionAM
rioxxterms.versionofrecord10.1002/hed.26100
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfHead & neck
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume42
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHardman, John
dc.contributor.icrauthorHarrington, Kevin
dc.contributor.icrauthorPaleri, Vinidh


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record